{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:18:26Z","timestamp":1773836306009,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,29]]},"DOI":"10.7759\/cureus.19993","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T14:29:46Z","timestamp":1638196186000},"source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic Dilemma of Paraneoplastic Rheumatic Disorders: Case Series and Narrative Review"],"prefix":"10.7759","author":[{"given":"Youngmin","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik W","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago J","family":"Miyara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Maria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine N","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanos","family":"Zafeiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Giannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Aronsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Molmenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20167-w","article-title":"Malignancy dominated with rheumatic manifestations: a retrospective single-center analysis","volume":"8","author":"Wen J","year":"2018","unstructured":"Wen J, Ouyang H, Yang R, Bo L, Zhang Y, Tang M, Liu Z. Malignancy dominated with rheumatic manifestations: a retrospective single-center analysis. Sci Rep. 2018, 8:1786. 10.1038\/s41598-018-20167-w","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328359e780","article-title":"Paraneoplastic rheumatologic syndromes","volume":"25","author":"Azar L","year":"2013","unstructured":"Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013, 25:44-49. 10.1097\/BOR.0b013e328359e780","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.02.001","article-title":"Rheumatic disorders as paraneoplastic syndromes","volume":"7","author":"Racanelli V","year":"2008","unstructured":"Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008, 7:352-58. 10.1016\/j.autrev.2008.02.001","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2000.0091","article-title":"Paraneoplastic rheumatic syndromes","volume":"14","author":"Fam AG","year":"2000","unstructured":"Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000, 14:515-33. 10.1053\/berh.2000.0091","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23085","article-title":"Vasculitides associated with malignancies: analysis of sixty patients","volume":"57","author":"Fain O","year":"2007","unstructured":"Fain O, Hamidou M, Cacoub P, et al.. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007, 57:1473-80. 10.1002\/art.23085","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X10387460","article-title":"Malignancy risk in vasculitis","volume":"3","author":"Kermani TA","year":"2011","unstructured":"Kermani TA, Warrington KJ, Amin S. Malignancy risk in vasculitis. Ther Adv Musculoskelet Dis. 2011, 3:55-63. 10.1177\/1759720X10387460","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.732","article-title":"Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009","volume":"66","author":"Podjasek JO","year":"2012","unstructured":"Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol. 2012, 66:e55-65. 10.1016\/j.jaad.2010.09.732","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70466-4","article-title":"Ovarian cancer presenting as leukocytoclastic vasculitis","volume":"40","author":"Stashower ME","year":"1999","unstructured":"Stashower ME, Rennie TA, Turiansky GW, Gilliland WR. Ovarian cancer presenting as leukocytoclastic vasculitis. J Am Acad Dermatol. 1999, 40:287-89. 10.1016\/s0190-9622(99)70466-4","journal-title":"J Am Acad Dermatol"},{"key":"ref9","article-title":"Leukocytoclastic vasculitis as the form of presentation of hepatocarcinoma (Article in Spanish)","volume":"19","author":"S\u00e1nchez-Angulo JI","year":"1996","unstructured":"S\u00e1nchez-Angulo JI, Ben\u00edtez-Rold\u00e1n A, Silgado-Rodr\u00edguez G, Ruiz-Campos J. Leukocytoclastic vasculitis as the form of presentation of hepatocarcinoma (Article in Spanish). Gastroenterol Hepatol. 1996, 19:255-58.","journal-title":"Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331215","article-title":"Cutaneous vasculitis associated with pheochromocytoma","volume":"33","author":"Kulp-Shorten CL","year":"1990","unstructured":"Kulp-Shorten CL, Rhodes RH, Peterson H, Callen JP. Cutaneous vasculitis associated with pheochromocytoma. Arthritis Rheum. 1990, 33:1852-56. 10.1002\/art.1780331215","journal-title":"Arthritis Rheum"},{"key":"ref11","article-title":"Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases","volume":"35","author":"Solans-Laqu\u00e9 R","year":"2008","unstructured":"Solans-Laqu\u00e9 R, Bosch-Gil JA, P\u00e9rez-Bocanegra C, Selva-O'Callaghan A, Sime\u00f3n-Aznar CP, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008, 35:294-304.","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette JC","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al.. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65:1-11. 10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030270","article-title":"Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis","volume":"19","author":"Bautz DJ","year":"2008","unstructured":"Bautz DJ, Preston GA, Lionaki S, et al.. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008, 19:2421-29. 10.1681\/ASN.2008030270","journal-title":"J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/ar4325","article-title":"Role of neutrophils in systemic autoimmune diseases","volume":"15","author":"Kaplan MJ","year":"2013","unstructured":"Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013, 15:219. 10.1186\/ar4325","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.07.001","article-title":"Cutaneous vasculitis in breast cancer treated with chemotherapy","volume":"129","author":"Wong M","year":"2008","unstructured":"Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol. 2008, 129:3-9. 10.1016\/j.clim.2008.07.001","journal-title":"Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.03.034","article-title":"Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report","volume":"11","author":"Peterlin P","year":"2011","unstructured":"Peterlin P, Ponge T, Blin N, Moreau P, Hamidou M, Agard C. Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report. Clin Lymphoma Myeloma Leuk. 2011, 11:373-74. 10.1016\/j.clml.2011.03.034","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000009","article-title":"The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features","volume":"92","author":"Loricera J","year":"2013","unstructured":"Loricera J, Calvo-R\u00edo V, Ortiz-Sanju\u00e1n F, et al.. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore). 2013, 92:331-43. 10.1097\/MD.0000000000000009","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering MC","year":"2013","unstructured":"Pickering MC, D'Agati VD, Nester CM, et al.. C3 glomerulopathy: consensus report. Kidney Int. 2013, 84:1079-89. 10.1038\/ki.2013.377","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 glomerulopathy","volume":"32","author":"Riedl M","year":"2017","unstructured":"Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 2017, 32:43-57. 10.1007\/s00467-015-3310-4","journal-title":"Pediatr Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith RJ","year":"2019","unstructured":"Smith RJ, Appel GB, Blom AM, et al.. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019, 15:129-43. 10.1038\/s41581-018-0107-2","journal-title":"Nat Rev Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10364.1","article-title":"C3 glomerulopathy","volume":"6","author":"Cook HT","year":"2017","unstructured":"Cook HT. C3 glomerulopathy. F1000Res. 2017, 6:248. 10.12688\/f1000research.10364.1","journal-title":"F1000Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000479014","article-title":"Immunosuppressive treatment in C3 glomerulopathy: time to reconsider our approach","volume":"46","author":"Tesar V","year":"2017","unstructured":"Tesar V, Hruskova Z. Immunosuppressive treatment in C3 glomerulopathy: time to reconsider our approach. Am J Nephrol. 2017, 46:93-95. 10.1159\/000479014","journal-title":"Am J Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig\u00a0is a distinct subtype","volume":"94","author":"Ravindran A","year":"2018","unstructured":"Ravindran A, Fervenza FC, Smith RJ, Sethi S. C3 glomerulopathy associated with monoclonal Ig\u00a0is a distinct subtype. Kidney Int. 2018, 94:178-86. 10.1016\/j.kint.2018.01.037","journal-title":"Kidney Int"},{"key":"ref24","article-title":"Autoimmune pancreatitis and IgG4-related systemic diseases","volume":"3","author":"Zhang L","year":"2010","unstructured":"Zhang L, Smyrk TC. Autoimmune pancreatitis and IgG4-related systemic diseases. Int J Clin Exp Pathol. 2010, 3:491-504.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0184-7","article-title":"Current concept of autoimmune pancreatitis and IgG4-related disease","volume":"113","author":"Okazaki K","year":"2018","unstructured":"Okazaki K, Uchida K. Current concept of autoimmune pancreatitis and IgG4-related disease. Am J Gastroenterol. 2018, 113:1412-16. 10.1038\/s41395-018-0184-7","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1354698","article-title":"Diagnostic and treatment workup for IgG4-related disease","volume":"13","author":"Abraham M","year":"2017","unstructured":"Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Rev Clin Immunol. 2017, 13:867-75. 10.1080\/1744666X.2017.1354698","journal-title":"Expert Rev Clin Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-017-2275-z","article-title":"IgG4-related disease: with emphasis on the biopsy diagnosis of autoimmune pancreatitis and sclerosing cholangitis","volume":"472","author":"Detlefsen S","year":"2018","unstructured":"Detlefsen S, Kl\u00f6ppel G. IgG4-related disease: with emphasis on the biopsy diagnosis of autoimmune pancreatitis and sclerosing cholangitis. Virchows Arch. 2018, 472:545-56. 10.1007\/s00428-017-2275-z","journal-title":"Virchows Arch"},{"key":"ref28","article-title":"Systemic sclerosis (Article in Polish)","author":"Kowal-Bielecka O","year":"2016","unstructured":"Kowal-Bielecka O, Kuryliszyn-Moskal A. Systemic sclerosis (Article in Polish). Reumatologia\/Rheumatology Supplements. 2016, 51-55.","journal-title":"Reumatologia\/Rheumatology Supplements"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000222","article-title":"Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening","volume":"27","author":"Shah AA","year":"2015","unstructured":"Shah AA, Casciola-Rosen L. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol. 2015, 27:563-70. 10.1097\/BOR.0000000000000222","journal-title":"Curr Opin Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000755","article-title":"Cancer and scleroderma: recent insights","volume":"32","author":"Morrisroe K","year":"2020","unstructured":"Morrisroe K, Nikpour M. Cancer and scleroderma: recent insights. Curr Opin Rheumatol. 2020, 32:479-87. 10.1097\/BOR.0000000000000755","journal-title":"Curr Opin Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802642062","article-title":"Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre","volume":"38","author":"Kang KY","year":"2009","unstructured":"Kang KY, Yim HW, Kim IJ, Yoon JU, Ju JH, Kim HY, Park SH. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 2009, 38:299-303. 10.1080\/03009740802642062","journal-title":"Scand J Rheumatol"},{"key":"ref32","article-title":"Increased incidence of carcinoma of the tongue in patients with systemic sclerosis","volume":"32","author":"Derk CT","year":"2005","unstructured":"Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol. 2005, 32:637-41.","journal-title":"J Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2016.60220","article-title":"Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome - description of two cases","volume":"54","author":"Marek M","year":"2016","unstructured":"Marek M, Rudny R. Scleroderma of geriatric age and scleroderma-like paraneoplastic syndrome - description of two cases. Reumatologia. 2016, 54:91-94. 10.5114\/reum.2016.60220","journal-title":"Reumatologia"},{"key":"ref34","article-title":"A cohort study of cancer incidence in systemic sclerosis","volume":"33","author":"Derk CT","year":"2006","unstructured":"Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006, 33:1113-16.","journal-title":"J Rheumatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner R","year":"2015","unstructured":"Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015, 5:e006389. 10.1136\/bmjopen-2014-006389","journal-title":"BMJ Open"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases","volume":"158","author":"Spencer-Green G","year":"1998","unstructured":"Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998, 158:595-600. 10.1001\/archinte.158.6.595","journal-title":"Arch Intern Med"},{"key":"ref37","article-title":"Raynaud Disease","author":"Musa R","year":"2021","unstructured":"Musa R, Qurie A. Raynaud Disease. StatPearls (Internet). 2020 (ed): StatPearls Publishing, Treasure Island (FL); 2021."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.03.2012.5985","article-title":"Paraneoplastic Raynaud's phenomenon manifesting before the diagnosis of lung cancer","volume":"2012","author":"Madabhavi I","year":"2012","unstructured":"Madabhavi I, Revannasiddaiah S, Rastogi M, Gupta MK. Paraneoplastic Raynaud's phenomenon manifesting before the diagnosis of lung cancer. BMJ Case Rep. 2012, 2012:bcr0320125985. 10.1136\/bcr.03.2012.5985","journal-title":"BMJ Case Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100575","article-title":"Paraneoplastic Raynaud phenomenon associated with metastatic ovarian cancer: a case report and review of the literature","volume":"33","author":"Lai TS","year":"2020","unstructured":"Lai TS, Shim MR, Shin D, Zakhour M. Paraneoplastic Raynaud phenomenon associated with metastatic ovarian cancer: a case report and review of the literature. Gynecol Oncol Rep. 2020, 33:100575. 10.1016\/j.gore.2020.100575","journal-title":"Gynecol Oncol Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801917-7.00054-1","article-title":"Chapter 54 - Drug-Induced Lupus","author":"Dooley MA","year":"2016","unstructured":"Dooley MA. Chapter 54 - Drug-Induced Lupus. Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects. Tsokos GC (ed): Elsevier, London; 2016. 473-79. 10.1016\/B978-0-12-801917-7.00054-1"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omy131","article-title":"Paraneoplastic systemic lupus erythematosus associated with colorectal cancer","volume":"2019","author":"Rees MJ","year":"2019","unstructured":"Rees MJ, Steinberg A, Romas E, Ford S, Roberts V, Ierino FL. Paraneoplastic systemic lupus erythematosus associated with colorectal cancer. Oxf Med Case Reports. 2019, 2019:omy131. 10.1093\/omcr\/omy131","journal-title":"Oxf Med Case Reports"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2012.10.015","article-title":"Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus","volume":"9","author":"Hidalgo-Conde A","year":"2013","unstructured":"Hidalgo-Conde A, de Haro Liger M, Abarca-Costalago M, \u00c1lvarez P\u00e9rez M, Valdivielso-Felices P, Gonz\u00e1lez-Santos P, Fern\u00e1ndez-Nebro A. Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus. Reumatol Clin. 2013, 9:359-64. 10.1016\/j.reuma.2012.10.015","journal-title":"Reumatol Clin"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320981765","article-title":"\"It's not lupus\". A placental site trophoblastic tumor presenting as a lupus-like paraneoplastic syndrome. A grand round case","volume":"30","author":"van der Lely SJ","year":"2021","unstructured":"van der Lely SJ, Boorsma J, Hilhorst M, Kers J, Roelofs J, Jakulj L, van Onna M. \"It's not lupus\". A placental site trophoblastic tumor presenting as a lupus-like paraneoplastic syndrome. A grand round case. Lupus. 2021, 30:495-501. 10.1177\/0961203320981765","journal-title":"Lupus"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04356-y","article-title":"Lung cancer mimicking systemic lupus erythematosus: case-based review","volume":"41","author":"Liu J","year":"2021","unstructured":"Liu J, Hu S, Niu M, Wang H, Wang Y, Tang N, Liu B. Lung cancer mimicking systemic lupus erythematosus: case-based review. Rheumatol Int. 2021, 41:981-86. 10.1007\/s00296-019-04356-y","journal-title":"Rheumatol Int"},{"key":"ref45","article-title":"Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis in breast carcinoma?","volume":"36","author":"Dertlio\u011flu SB","year":"2021","unstructured":"Dertlio\u011flu SB, Yildiz B, Kili\u00e7arslan A, Solmaz \u00d6A, Karabulut P . Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis in breast carcinoma?.  Turkish J Oncol. 2021, 36:121-24.","journal-title":"Turkish J Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez011","article-title":"Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin's lymphoma: a nationwide population-based study","volume":"58","author":"Wang LH","year":"2019","unstructured":"Wang LH, Wang WM, Lin SH, Shieh CC. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin's lymphoma: a nationwide population-based study. Rheumatology (Oxford). 2019, 58:1245-49. 10.1093\/rheumatology\/kez011","journal-title":"Rheumatology (Oxford)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01900.x","article-title":"Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?","volume":"30","author":"Chaudhry SI","year":"2005","unstructured":"Chaudhry SI, Murphy LA, White IR. Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?. Clin Exp Dermatol. 2005, 30:655-58. 10.1111\/j.1365-2230.2005.01900.x","journal-title":"Clin Exp Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2019.1571880","article-title":"Cancer-associated myositis: an elusive entity","volume":"9","author":"Fayyaz B","year":"2019","unstructured":"Fayyaz B, Rehman HJ, Uqdah H. Cancer-associated myositis: an elusive entity. J Community Hosp Intern Med Perspect. 2019, 9:45-49. 10.1080\/20009666.2019.1571880","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00756-4","article-title":"Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort","volume":"26","author":"Andr\u00e1s C","year":"2020","unstructured":"Andr\u00e1s C, Bodoki L, Nagy-Vincze M, Griger Z, Csiki E, Dank\u00f3 K. Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a Hungarian myositis cohort. Pathol Oncol Res. 2020, 26:1749-55. 10.1007\/s12253-019-00756-4","journal-title":"Pathol Oncol Res"},{"key":"ref50","article-title":"The polymyositis and dermatomyositis syndrome","author":"Engel AG","year":"2004","unstructured":"Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. Myology, 3rd edition. Engel AG (ed): McGraw-Hill Education, New York; 2004. 1335-83."},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-014-0062-2","article-title":"Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis","volume":"5","author":"Vattemi G","year":"2014","unstructured":"Vattemi G, Mirabella M, Guglielmi V, Lucchini M, Tomelleri G, Ghirardello A, Doria A. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Auto Immun Highlights. 2014, 5:77-85. 10.1007\/s13317-014-0062-2","journal-title":"Auto Immun Highlights"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study","volume":"134","author":"Buchbinder R","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001, 134:1087-95. 10.7326\/0003-4819-134-12-200106190-00008","journal-title":"Ann Intern Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-9993(97)90043-5","article-title":"Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision","volume":"78","author":"Jensen ML","year":"1997","unstructured":"Jensen ML, Wieting JM, Andary MT, Fankhauser MJ, Jones MJ. Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. Arch Phys Med Rehabil. 1997, 78:327-29. 10.1016\/s0003-9993(97)90043-5","journal-title":"Arch Phys Med Rehabil"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8511-x","article-title":"Idiopathic inflammatory myopathies and malignancy: a comprehensive review","volume":"52","author":"Tiniakou E","year":"2017","unstructured":"Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017, 52:20-33. 10.1007\/s12016-015-8511-x","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000546","article-title":"Inclusion body myositis and chronic lymphocytic leukemia: a case series","volume":"83","author":"Beck EH","year":"2014","unstructured":"Beck EH, Amato AA, Greenberg SA. Inclusion body myositis and chronic lymphocytic leukemia: a case series. Neurology. 2014, 83:98-99. 10.1212\/WNL.0000000000000546","journal-title":"Neurology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang J","year":"2013","unstructured":"Wang J, Guo G, Chen G, Wu B, Lu L, Bao L. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol. 2013, 169:838-47. 10.1111\/bjd.12564","journal-title":"Br J Dermatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf E","year":"2018","unstructured":"Naddaf E, Barohn RJ, Dimachkie MM. Inclusion body myositis: update on pathogenesis and treatment. Neurotherapeutics. 2018, 15:995-1005. 10.1007\/s13311-018-0658-8","journal-title":"Neurotherapeutics"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie MM","year":"2014","unstructured":"Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014, 32:629-46. 10.1016\/j.ncl.2014.04.001","journal-title":"Neurol Clin"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094128","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu X","year":"2014","unstructured":"Lu X, Yang H, Shu X, et al.. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014, 9:e94128. 10.1371\/journal.pone.0094128","journal-title":"PLoS One"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello A","year":"2014","unstructured":"Ghirardello A, Borella E, Beggio M, Franceschini F, Fredi M, Doria A. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014, 5:69-75. 10.1007\/s13317-014-0060-4","journal-title":"Auto Immun Highlights"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang EH","year":"2016","unstructured":"Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford). 2016, 55:1631-41. 10.1093\/rheumatology\/kew215","journal-title":"Rheumatology (Oxford)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy H","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007, 66:1345-49. 10.1136\/ard.2006.068502","journal-title":"Ann Rheum Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-015-0047-z","article-title":"Thrombosis in vasculitis: from pathogenesis to treatment","volume":"13","author":"Emmi G","year":"2015","unstructured":"Emmi G, Silvestri E, Squatrito D, et al.. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015, 13:15. 10.1186\/s12959-015-0047-z","journal-title":"Thromb J"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.138","article-title":"Paraneoplastic syndromes in rheumatology","volume":"10","author":"Manger B","year":"2014","unstructured":"Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014, 10:662-70. 10.1038\/nrrheum.2014.138","journal-title":"Nat Rev Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1996.tb02940.x","article-title":"Rheumatic manifestations of the myelodysplastic syndromes: a comparative study","volume":"26","author":"Chandran G","year":"1996","unstructured":"Chandran G, Ahern MJ, Seshadri P, Coghlan D. Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. Aust N Z J Med. 1996, 26:683-88. 10.1111\/j.1445-5994.1996.tb02940.x","journal-title":"Aust N Z J Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12277","article-title":"Diagnostic dilemma of paraneoplastic arthritis: case series","volume":"17","author":"Kisacik B","year":"2014","unstructured":"Kisacik B, Onat AM, Kasifoglu T, et al.. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014, 17:640-45. 10.1111\/1756-185X.12277","journal-title":"Int J Rheum Dis"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2663","article-title":"Paraneoplastic inflammatory arthritis","volume":"10","author":"Rast F","year":"2018","unstructured":"Rast F, Parperis K, Amar S, Al-Charakh M. Paraneoplastic inflammatory arthritis. Cureus. 2018, 10:e2663. 10.7759\/cureus.2663","journal-title":"Cureus"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001202","article-title":"Paraneoplastic arthritides: insights to pathogenesis, diagnostic approach, and treatment","author":"Parperis K","year":"2019","unstructured":"Parperis K, Constantinidou A, Panos G. Paraneoplastic arthritides: insights to pathogenesis, diagnostic approach, and treatment. J Clin Rheumatol. 2019, (Epub ahead of print). 10.1097\/RHU.0000000000001202","journal-title":"J Clin Rheumatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2013.843762","article-title":"Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations","volume":"24","author":"Yamashita H","year":"2014","unstructured":"Yamashita H, Ueda Y, Ozaki T, et al.. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014, 24:492-98. 10.3109\/14397595.2013.843762","journal-title":"Mod Rheumatol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1294-8","article-title":"Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature","volume":"31","author":"Larson E","year":"2011","unstructured":"Larson E, Etwaru D, Siva C, Lawlor K. Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature. Rheumatol Int. 2011, 31:1635-38. 10.1007\/s00296-009-1294-8","journal-title":"Rheumatol Int"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2252-9","article-title":"Paraneoplastic rheumatic syndromes: report of eight cases and review of literature","volume":"32","author":"Hakkou J","year":"2012","unstructured":"Hakkou J, Rostom S, Bahiri R, Hajjaj-Hassouni N. Paraneoplastic rheumatic syndromes: report of eight cases and review of literature. Rheumatol Int. 2012, 32:1485-89. 10.1007\/s00296-011-2252-9","journal-title":"Rheumatol Int"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070086","article-title":"Characteristics and survival of 26 patients with paraneoplastic arthritis","volume":"67","author":"Morel J","year":"2008","unstructured":"Morel J, Deschamps V, Toussirot E, et al.. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008, 67:244-47. 10.1136\/ard.2007.070086","journal-title":"Ann Rheum Dis"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine M","year":"2019","unstructured":"Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (Oxford). 2019, 58:68-74. 10.1093\/rheumatology\/kez295","journal-title":"Rheumatology (Oxford)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir R","year":"2017","unstructured":"Belkhir R, Le Burel S, Dunogeant L, et al.. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017, 76:1747-50. 10.1136\/annrheumdis-2017-211216","journal-title":"Ann Rheum Dis"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa NS","year":"2017","unstructured":"Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by pembrolizumab: a case series. Mayo Clin Proc. 2017, 92:1158-63. 10.1016\/j.mayocp.2017.03.016","journal-title":"Mayo Clin Proc"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13432","article-title":"Bullous lupus under nivolumab treatment for lung cancer: a case report with systematic literature review","volume":"39","author":"Wouters A","year":"2019","unstructured":"Wouters A, Durieux V, Kolivras A, Meert AP, Sculier JP. Bullous lupus under nivolumab treatment for lung cancer: a case report with systematic literature review. Anticancer Res. 2019, 39:3003-3008. 10.21873\/anticanres.13432","journal-title":"Anticancer Res"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune\u2010related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli LC","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune\u2010related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017, 69:1751-63. 10.1002\/acr.23177","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter MD","year":"2018","unstructured":"Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol. 2018, 70:356-60. 10.1002\/art.40397","journal-title":"Arthritis Rheumatol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.018","article-title":"Rheumatologic symptoms in oncologic patients on PD-1 inhibitors","volume":"47","author":"Kuswanto WF","year":"2018","unstructured":"Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum. 2018, 47:907-10. 10.1016\/j.semarthrit.2017.10.018","journal-title":"Semin Arthritis Rheum"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1804362","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management","volume":"16","author":"Williams SG","year":"2020","unstructured":"Williams SG, Mollaeian A, Katz JD, Gupta S. Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Rev Clin Immunol. 2020, 16:771-785. 10.1080\/1744666X.2020.1804362","journal-title":"Expert Rev Clin Immunol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000281","article-title":"Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy","volume":"8","author":"Murray-Brown W","year":"2020","unstructured":"Murray-Brown W, Wilsdon TD, Weedon H, et al.. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother Cancer. 2020, 8:e000281. 10.1136\/jitc-2019-000281","journal-title":"J Immunother Cancer"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian MJ","year":"2019","unstructured":"Mooradian MJ, Nasrallah M, Gainor JF, et al.. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum. 2019, 48:1127-32. 10.1016\/j.semarthrit.2018.10.012","journal-title":"Semin Arthritis Rheum"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx531","article-title":"Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment","volume":"28","author":"Teyssonneau D","year":"2017","unstructured":"Teyssonneau D, Cousin S, Italiano A. Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Ann Oncol. 2017, 28:3108. 10.1093\/annonc\/mdx531","journal-title":"Ann Oncol"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe J","year":"2018","unstructured":"Leipe J, Christ LA, Arnoldi AP, et al.. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018, 4:e000714. 10.1136\/rmdopen-2018-000714","journal-title":"RMD Open"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy","volume":"77","author":"Le Burel S","year":"2018","unstructured":"Le Burel S, Champiat S, Routier E, et al.. Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy. Ann Rheum Dis. 2018, 77:468-70. 10.1136\/annrheumdis-2016-210820","journal-title":"Ann Rheum Dis"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner BM","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, et al.. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019, 24:1259-69. 10.1634\/theoncologist.2018-0823","journal-title":"Oncologist"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.322","article-title":"Nivolumab-induced sialadenitis","volume":"6","author":"Takahashi S","year":"2018","unstructured":"Takahashi S, Chieko X, Sakai T, Hirose S, Nakamura M. Nivolumab-induced sialadenitis. Respirol Case Rep. 2018, 6:e00322. 10.1002\/rcr2.322","journal-title":"Respirol Case Rep"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001012","article-title":"Immune checkpoint inhibitor-associated polymyalgia rheumatica\/giant cell arteritis occurring in a patient after treatment with nivolumab","author":"Betrains A","year":"2019","unstructured":"Betrains A, Blockmans DE. Immune checkpoint inhibitor-associated polymyalgia rheumatica\/giant cell arteritis occurring in a patient after treatment with nivolumab. J Clin Rheumatol. 2019, (Epub ahead of print). 10.1097\/RHU.0000000000001012","journal-title":"J Clin Rheumatol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","author":"Watanabe R","year":"2017","unstructured":"Watanabe R, Zhang H, Berry G, Goronzy JJ, Weyand CM. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am J Physiol Heart Circ Physiol. 2017, 312:H1052-59. 10.1152\/ajpheart.00024.2017","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/77115-diagnostic-dilemma-of-paraneoplastic-rheumatic-disorders-case-series-and-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:16Z","timestamp":1707507136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/77115-diagnostic-dilemma-of-paraneoplastic-rheumatic-disorders-case-series-and-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":89,"URL":"https:\/\/doi.org\/10.7759\/cureus.19993","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}